iTrack™ Canaloplasty to be Featured at the 2024 World Ophthalmology Congress (WOC)

California, USA, July 23, 2024 – Nova Eye Medical Limited, a medical technology company committed to advanced ophthalmic treatment technologies and devices, is pleased to announce that the Company's proprietary **iTrack™ canaloplasty technology** will be featured in the official scientific program of the 39th World Ophthalmology Congress (WOC), taking place in Vancouver, Canada from August 16th to 19th, 2024.

A summary of the iTrack™ posters at WOC 2024 is included below:

Loukman Ghouti (Canada), Nir Shoham-Hazon (Canada)
Management of Dislocated IOL and Uncontrolled Pseudoexfoliation Glaucoma With iTrack Advance Canaloplasty: A Case Report
Poster Reception (Poster Area)
Saturday, August 17, 2024 - Time: 18:15 PM – 18:45 PM

Jia Ru Liu (Canada), Paul Harasymowycz (Canada), David Lubeck (USA), Keith Barton (UK), Nathan Kerr (Australia)
Canaloplasty performed with the iTrack microcatheter to reduce IOP in uncontrolled glaucoma eyes
Poster Pod 3 - Glaucoma Presentations
Sunday, August 18, 2024 - Time: 12:45pm – 12:50pm

Full session details can be accessed via the WOC program: https://icowoc.org/program/

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include the iTrack™ portfolio of canaloplasty devices for the treatment of glaucoma. The Company also manufactures and sells the proprietary Molteno3® glaucoma drainage device for the treatment of severe or complex glaucoma. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by sales offices in Adelaide, Australia and Berlin,

Germany, and a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

ABOUT CANALOPLASTY

First introduced in 2008, canaloplasty is a surgical treatment for glaucoma that targets the main sites of outflow resistance in the conventional outflow pathway: the trabecular meshwork, Schlemm's canal, and the distal collector channels. Based on the same principles as angioplasty, a flexible microcatheter is cannulated 360 degrees around Schlemm's canal during the procedure to manually break and remove blockages. Next, viscoelastic fluid is injected into Schlemm's canal as the microcatheter is withdrawn to dilate the distal outflow system and to improve the function of the trabecular meshwork.

The iTrack™ Advance canaloplasty device has a US Food and Drug Administration (FDA) 510(k) and CE Mark (Conformité Européenne) for the treatment of open-angle glaucoma.

The iTrack™ Advance canaloplasty device has been cleared for the indication of fluid infusion and aspiration during surgery, and for catheterization and viscodilation of Schlemm's canal to reduce intraocular pressure in adult patients with open-angle glaucoma.

For additional information about canaloplasty and the *iTrack™ Advance*, including safety information, please visit: https://itrack-advance.com

For media enquiries, please contact:
Kate Hunt: Nova Eye Chief Commercial Officer - khunt@nova-eye.com
Giorgio Pirazzini: GP Communications – giorgio@gpcommunications.eu